{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-300417","form_type":"8-K","ticker":"EQ","cik":"0001746466","company_name":"Equillium, Inc.","filed_at":"2023-12-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.296257+00:00","generated_at":"2026-06-07T09:13:07.248720+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Equillium completes EQ101 Phase 2 enrollment for alopecia areata; advances EQ302 over EQ102","bullets":["Completed enrollment of 36 patients in EQ101 Phase 2 study for alopecia areata; topline data expected Q2 2024.","Baseline: mean SALT score of 76; 50% severe (SALT 50-94), 33% very severe (SALT >95%).","75% of patients had prior treatments; 11 received oral treatments including JAK inhibitors.","EQ302 oral multi-cytokine inhibitor of IL-15 & IL-21 to be advanced for GI/skin diseases instead of EQ102."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-300417","json":"https://secwatch.observer/filing/0001193125-23-300417.json","markdown":"https://secwatch.observer/filing/0001193125-23-300417.md","text":"https://secwatch.observer/filing/0001193125-23-300417.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1746466/000119312523300417/0001193125-23-300417-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1746466/000119312523300417/d575238d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T09:13:07.248720+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}